Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
暂无分享，去创建一个
D. Schadendorf | K. Flaherty | J. Larkin | M. Casey | A. Ribas | C. Garbe | M. Mandalà | H. Gogas | J. Grob | M. Millward | V. Chiarion-Sileni | G. Long | D. Demarini | C. Robert | C. Lebbé | M. Amonkar | G. Aktan | P. Nathan | I. Bondarenko | D. Stroyakovskiy | E. Levchenko | F. de Braud | J. Irani | A. Arance